Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer
https://doi.org/10.21518/2079-701X-2018-19-122-125
Abstract
At the present time, a small group of patients with oligometastases (who have a solitary metastatic lesion in another organ along with the primary tumour of the lung) is differentiated among the patients with metastatic lung cancer. A total of 14 patients of the study citied in this article underwent a comprehensive treatment of oligometastatic non-small cell lung cancer (ONSCLC), which included systemic therapy and local influence on solitary metastasis. The median overall survival for this group was 20 months (16.0–32.6, CI 95%). The 1-year and 2-year overall survival rates accounted for 84.5 and 65.7%, respectively. The findings of the study demonstrate the possibilities of an aggressive approach to the treatment of patients with ONLDLC.
About the Authors
D. I. Yudin
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
K. K. Laktionov
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
D. T. Marinov
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
V. V. Breder
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
A. K. Allakhverdiev
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
T. N. Borisova
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
A. H. Bekyashev
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
K. P. Laktionov
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
V. A. Aleshin
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
M. S. Ardzinba
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
References
1. Kaprin AD, Starinsky VV, Petrova GV. The state of cancer care in Russia, 2015. M., 2016.
2. Billing PS, Miller DL, Allen MS, et al. Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg, 2001, 122: 548-53.
3. Bonnette P, Puyo P, Gabriel C, et al. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest, 2001, 119: 1469-75.
4. DeLuzio M, Moores C, Dhamija A, Wang Z, Cha C, Boffa D, Detterbeck F, Kim A. Resection of oligometastatic lung cancer to the pancreas may yield a survival benefit in select patients – A systematic review. Published Online: April 03, 2015.
5. Endo C, Hasumi T, Matsumura Y, Sato N, Deguchi H, Oizumi H, Sagawa M, Tsushima T, Takahashi S, Shibuya J, Hirose M, Kondo T. A Prospective Study of Surgical Procedures for Patients With Oligometastatic Non-Small Cell Lung Cancer. J Thorac Cardiovasc Surg, 2014 Mar 19.
6. Flannery TW, Suntharalingam M, Kwok Y, Koffman BH, Amin PP, Chin LS, et al. Gamma knife stereotactic radiosurgery for synchronous versus metachronous solitary brain metastases from non-small cell lung cancer. Lung Cancer, 2003, 42: 327-33.
7. Folkert M, Timmerman R. Review of Treatment Options for Oligometastatic Non–Small Cell Lung Cancer. Clinical Advances in Hematology & Oncology, 2015 March, 13(Issue 3): 186-193.
8. Gray PJ, Mak RH, Yeap BY, Cryer SK, Pinnell NE, Christianson LW, Sher DJ, Arvold ND, Baldini EH, Chen AB, Kozono DE, Swanson SJ, Jackman DM, Alexander BM. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Clin Cancer Res, 2014 Jul 10.
9. Griffioen GH, Toguri D, Dahele M, Warner A, de Haan PF, Rodrigues GB, Slotman BJ, Yaremko BP, Senan S, Palma DA. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer, 2013 Oct, 82(1): 95-102.
10. Girard N, Cottin V, Tronc F, et al. Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases. Lung Cancer, 2006, 53(1): 51–58.
11. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol, 1995 Jan, 13(1): 8-10.
12. Hung J, Durrani H, Aljumaily R, Arastu H, Leinweber C, Rosenman J, Walker P. Oligometastatic non-small cell lung cancer treated with curative intent. J Clin Oncol, 2014, 32(suppl, abstr e19034).
13. Iwasaki A, Shirakusa T, Yoshinaga Y, Enatsu S, Yamamoto M. Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor. European Journal of Cardio-thoracic Surgery, 2004, 26(3): 488–493.
14. Mercier O, Fadel E, de Perrot M, et al. Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer. J Thorac Cardiovasc Surg, 2005, 130: 136-40.
15. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med, 1990, 322(8): 494-500.
16. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E, ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012, 23(suppl 7): vii56-vii64.
17. Raz DJ, Lanuti M, Gaissert HC, et al. Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma. Ann Thorac Surg, 2011, 92: 1788-92, discussion 1793.
18. Schiller J, Harrington D, Belani C P, Langer C, Sandler A, Krook J, Zhu J, Johnsonn D J Comparison of four chemotherapy regiments for advanced non-small-cell lung cancer. Med, 2002 January 10, 346(2): 92-8.
19. Simonova G, Liscak R, Novotny J Jr, Novotný J. Solitary brain metastases treated with the Leksell gamma knife: prognostic factors for patients. Radiother Oncol, 2000, 57: 207-13.
20. Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol, 2008, 26: 1142-7.
Review
For citations:
Yudin DI, Laktionov KK, Marinov DT, Breder VV, Allakhverdiev AK, Borisova TN, Bekyashev AH, Laktionov KP, Aleshin VA, Ardzinba MS. Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer. Meditsinskiy sovet = Medical Council. 2018;(19):122-125. (In Russ.) https://doi.org/10.21518/2079-701X-2018-19-122-125
Views:
686
Email this article 